Program Contents
| Session 1 | The science to inform our decision making |
| Session 2 | Reviewing the clinical evidence -- considering the role of calcineurin inhibitors |
| Session 3 | New immunosuppressive agents in kidney transplantation |
| Session 4 | Post-transplant malignancy |
| Session 5 | The non-immunosuppressive properties of mTOR-inhibition |
| Session 6 | Conclusions from the symposium |






